连续性肾脏替代疗法在重症医学科中的合理应用评价

杨文超, 刘馨侠, 王岩, 范特, 胡萨萨, 王茂义, 董亚琳

中国药学杂志 ›› 2016, Vol. 51 ›› Issue (11) : 935-941.

PDF(1028 KB)
PDF(1028 KB)
中国药学杂志 ›› 2016, Vol. 51 ›› Issue (11) : 935-941. DOI: 10.11669/cpj.2016.11.015
论著

连续性肾脏替代疗法在重症医学科中的合理应用评价

  • 杨文超, 刘馨侠, 王岩, 范特, 胡萨萨, 王茂义, 董亚琳*
作者信息 +

The Evaluation of Reasonable Application of CRRT in ICU

  • YANG Wen-chao, LIU Xin-xia, WANG Yan, FAN Te, HU Sa-sa, WANG Mao-yi, DONG Ya-lin*
Author information +
文章历史 +

摘要

目的 评价连续性肾脏替代疗法(continuous renal replacement therapy,CRRT)在重症医学科(intensive care unit,ICU)患者中的应用现状。方法 回顾性分析2014年1~12月西安交通大学第一附属医院ICU的CRRT适应证患者171例的临床资料,分为行CRRT组(n=148)和未行CRRT组(n=23),其中CRRT组分为两个亚组:连续静脉-静脉血液滤过(continuous veno-venous hemofiltration,CVVH)组(n=66)和非CVVH组(n=82)。行CRRT治疗的148例患者按治疗效果分为好转组(n=83)、无好转组(n=46)及死亡组(n=19);行CVVH治疗的66例患者按治疗效果分好转组(n=39)和无好转组(n=27)。对171例患者的适应证及行CRRT的148例患者的首选抗凝方案、置管方案、置换液、CRRT管路冲洗的5个指标进行统计评估,并对患者临床数据与CRRT治疗模式和患者治疗效果(好转、无好转及死亡)之间的相关性进行统计学分析。结果 171例患者的适应证及行CRRT的148例患者的首选抗凝方案、置管方案、置换液、CRRT管路冲洗这5个方面指标的合理率分别为86.55%、84.76%、66.89%、100%、100%。单因素分析显示,在3种治疗模式下(CVVH组、非CVVH组、未行CRRT组),171例患者的尿素氮基线(P=0.035)、肌酐基线(P=0.007)、治疗前3天每日尿量中d2(P=0.004)、d3(P=0.034),差异有统计学意义; CRRT组中首选置管方案与患者存活率(P=0.01)间差异有统计学意义、首选置管方案与存活患者预后之间(P=0.007)差异有统计学意义。多因素分析显示,CVVH组中ICU入住时长[P=0.005,OR:0.734,95%CI(0.592, 0.910)]、首选置管方案[P=0.016,OR:5.302,95%CI(1.369, 20.527)],与患者预后呈显著相关性。结论 本研究中,171例患者的适应证及行CRRT的148例患者的首选抗凝方案、置管方案这3个指标存在不合理性,其不合理率分别为13.45%、15.24%、33.11%。临床药师应该结合患者的病理生理基础特征,考虑到ICU患者用药的复杂性,对患者行CRRT过程中的整体化用药,进行重点追踪、个体化监测,提高临床药物治疗水平,发挥药学人员在临床药物治疗管理方面的优势。

Abstract

OBJECTIVE To evaluate the status of application of continuous renal replacement therapy (CRRT) in patients in the intensive care unit (ICU). METHODS The clinical data of 171 ICU patients who had indications for CRRT in the First Affiliated Hospital of Xi′an Jiaotong University from January to December 2014 were retrospective analyzed. The patients were divided into non-CRRT group (n=23) and CRRT group (n=148) which was composed of continuous veno-venous hemofiltration (CVVH) group (n=66) and non-CVVH group (n=82). Among the 148 CRRT patients, 83 had improvement, 46 had no improvement, and 19 died. Among the 66 CVVH patients, 39 had improvement, and 27 had no improvement. The indications of the 171 patients and several aspects of the CRRT group including anticoagulation regimen, catheterization program, replacement fluid, and CRRT pipe flushing were statistically analyzed. And the correlations between the clinical data, CRRT mode, and efficacy were evaluated. RESULTS The rate of rational indications of 171 patients was 86.55%, meanwhile the rates of the reasonability of anticoagulation method, catheterization program, replacement fluid, and CRRT pipe flushing of the CRRT group were 84.76%, 66.89%, 100%, and 100%, respectively. Single factor analysis showed that the levels of BUN (P=0.035) and creatinine (P=0.007) at baseline and the urine output on the third day (P=0.034) had statistically significant difference among the CVVH group, non-CVVH group, and non-CRRT group. There were also significant differences in the survival rate (P=0.01) and prognosis of survivals (P=0.007) in CRRT group among different catheterization programs. Multivariate analysis indicated that there was significant correlation between the lengh of stay in ICU [P=0.005, OR:0.734, 95% CI(0. 592,0.910)], catheterization program [P=0.016, OR:5.302,95%CI(1.369,20.527)] and prognosis. CONCLUSION The indications, anticoagulation method, and catheterization program of the CRRT group were partially unreasonable in the 171 patients in our study, and the unreasonability rates were 13.45%, 15.24%, and 33.11%, respectively. Clinical pharmacists should focus on the drug regimens and individual monitoring of ICU patients in the process of CRRT, considering their pathophysiological characteristics and complexity of medical therapeutic schemes.

关键词

连续性肾脏替代疗法 / 重症医学科 / 连续静脉-静脉血液滤过

Key words

continuous renal replacement therapy / intensive care unit / continuous veno-venous hemofiltration

引用本文

导出引用
杨文超, 刘馨侠, 王岩, 范特, 胡萨萨, 王茂义, 董亚琳. 连续性肾脏替代疗法在重症医学科中的合理应用评价[J]. 中国药学杂志, 2016, 51(11): 935-941 https://doi.org/10.11669/cpj.2016.11.015
YANG Wen-chao, LIU Xin-xia, WANG Yan, FAN Te, HU Sa-sa, WANG Mao-yi, DONG Ya-lin. The Evaluation of Reasonable Application of CRRT in ICU[J]. Chinese Pharmaceutical Journal, 2016, 51(11): 935-941 https://doi.org/10.11669/cpj.2016.11.015
中图分类号: R969.3   

参考文献

[1] JING S P, ZHU Z Y, XIAO Y H, et al. Continuous renal replacement therapy in patients with antibacterial drug dose adjustment of clinical pharmacists intervention effects were retrospectively analyzed [J]. Chin Pharm J(中国药学杂志), 2013, 48 (10):827-830.
[2] JI D X, GONG D H. The characteristics and development of continuous renal replacement therapy [J]. Chin J Blood Purif(中国血液净化), 2006, 5(9):647-649.
[3] WANG J Q, GAO B H, LIU B, et al. Application of continuous veno-venous hemofiltration in ICU [J]. Chin J Blood Purif(中国血液净化), 2002, 1(4):17-19.
[4] IWAGAMI M, YASUNAGA H, NOIRI E, et al. Choice of renal replacement therapy modality in intensive care units:data from a Japanese Nationwide Administrative Claim Database[J]. J Critical Care, 2014,30(2):381-385.
[5] CAMM A J, KIRCHHOF P, LIP G Y, et al. Guidelines for the management of atrial fibrillation :the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) [J]. Europace, 2010, 12(10):1360-1420.
[6] YU J H, XU Y. Effective evaluation of regional heparin anticoahulation in continuous renal replacement therapy [J]. J Pract Med(实用医学杂志), 2014, 30(13):2157-2159.
[7] CHEN M X. Blood Purification Standard Operating Procedure(血液净化标准操作规程)[M]. Beijing:People′s Military Medical Press, 2010:100-101.
[8] MONCHI M, BERGHMANS D, LEDOUX D, et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration:a prospective randomized study[J]. Intensive Care Med, 2004, 30(2):260-265.
[9] REEVES J H, CUMMING A R, GALLAGHER L, et al. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration[J]. Crit Care Med, 1999, 27(10):2224-2228.
[10] ABRAMSON S, NILES J L. Anticoagulation in continuous renal replacement therapy[J]. Curr Opin Neurobiol Hypertens, 1999, 8(6):701-707.
[11] RONCO C, LEVIN A, WARNOCK D G, et al. Improving outcomes from acute kidney injury (AKI):report on an initiative[J]. Int J Artificial Organs, 2007, 30(5):373-376.
[12] ZHANG K Y, XU B, WU C Y, et al. Regional citrate plus low dose of low molecular weight heparins in continuous veno-venous hemofiltration[J]. Chin J Nephrol Dial Transplant(肾脏病与透析肾移植杂志), 2012, 21(4):311-316.
[13] YANG D S, YANG P, ZHANG Y, et al. Different anticoagulant techniques in severe sepsis application of CRRT treatment in patients with thrombocytopenia[J]. Chongqing Med(重庆医学), 2014, 43(28):3724-3726.
[14] GONG D H, JI D X, XU B, et al. Regional citrate anticoagulation in heparin-contraindicative critically ill patients during continuous venovenous hemofiltration[J]. Chin J Nephrol Dial Transplant(肾脏病与透析肾移植杂志), 2002, 11(6):510-514.
[15] PENG J M, WANG Y S, WENG L, et al. Comparative studies with regional citrate anticoagulation and system heparin anticoagulation for continuous venovenous hemofiltration in sever patients[J]. Chin J Pract Med(中国实用内科杂), 2010, 30(8):717-719.
[16] JIA L N, GUI B S. The application progress of citrate anticoagulation for blood purification[J]. Int J Transplant Hemopurification(国际移植与血液净化杂志), 2006, 4(4):7-10.
[17] BROPHY P D, SOMERS M J, BAUM M A, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT)[J]. Nephrol Dial Transplant, 2005, 20(7):1416-1421.
[18] PARIENTI J J, THIRION M, MGARBANE B, et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy:a randomized controlled trial [J]. Jama, 2008, 299(20):2413-2422.
[19] CANAUD B, DESMEULES S, KLOUCHE K, et al. Vascular access for dialysis in the intensive care unit [J]. Best Pract Res Clin Anaesthesiol, 2004,18(1):159-174.
[20] HUANG D Y, RAO H Q, ZHOU D R, et al. Clinical efficacy about continuous blood purification (cbp) treatment in patients with severe sepsis[J]. Mod Hosp(现代医院), 2013,13(1):35-37.
[21] UCHINO S, KELLUM J A, BELLOMO R, et al. Acute renal failure in critically ill patients:a multinational, multicenter study [J]. Jama, 2005, 294(7):813-818.
[22] BELL M, SWING, GRANATH F, et al. Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure[J]. Intensive Care Med, 2007, 33(5):773-780.
[23] WU M S, ZHAO X Q, ZHOU H W. Application and prognostic analysis of continuous blood purification in the treatment of patients complicated with multiplp organ dysfunction syndrome and acute renal failure in ICU [J]. Intern Med Chin(内科), 2008, 3(5):22-25.
[24] LIU S Q, GUO J Y, BAO Z. Therapeutic effects of continuous renal replacement in patients with multiple organ dysfunction syndrome in ICU [J]. Med J Chin PLA(解放军医学杂志), 2013, 38(5):383-386.
[25] SU W, FU Y H, XU D L, et al. The effect of prognosis of wound complicated with acute kidney injury patients treated with continuous veno-venous hemofiltration therapy [J]. J Pract Med(实用医学杂志), 2014, 30(15):2455-2458.
PDF(1028 KB)

Accesses

Citation

Detail

段落导航
相关文章

/